NCT06709885 is a Phase 2 clinical trial of Chidamide + Tislelizumab + chemotherapy (CapeOX ) in Colon Adenocarcinoma, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

What drugs are being tested in NCT06709885?

Interventions in NCT06709885: Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX.

What condition does NCT06709885 study?

NCT06709885 studies Colon Adenocarcinoma.

Is NCT06709885 still recruiting?

NCT06709885 is currently recruiting now. Last updated 29 November 2024.

Last reviewed 2024-11-29 · How we verify

NCT06709885

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

Recruiting now Phase 2 Last updated 29 November 2024

What this trial tests

Phase 2 trial testing Chidamide + Tislelizumab + chemotherapy (CapeOX ) in Colon Adenocarcinoma in 100 participants. Currently enrolling.

Timeline

15 October 2024

Primary endpoint
30 September 2025

30 September 2027

Quick facts

Lead sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	15 October 2024
Primary completion	30 September 2025
Estimated completion	30 September 2027
Sites	1 location across China

Drugs / interventions tested

Chidamide + Tislelizumab + chemotherapy (CapeOX ) — full drug profile →
CapeOX — full drug profile →

Conditions studied

Colon Adenocarcinoma — all drugs for Colon Adenocarcinoma →

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Who can join

18 and older, any sex, with Colon Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer. The main questions it aims to answer are: Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadjuvant therapy?

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Role of neoadjuvant therapies in locally advanced colon cancer.
Castria TB, Lenz G, Valagni G, Kim RD. · · 2025 · cited 1× · PMID 40736234 · DOI 10.1097/cm9.0000000000003756
Non-Histone Lysine Modifications in Tumor Microenvironment: Mechanisms and Therapeutic Opportunities.
Sun K, Xiao S, Huang Q, Zhang S, et al · · 2025 · PMID 41303712 · DOI 10.3390/ijms262211229

Verify or expand the search:

Other recruiting trials for Colon Adenocarcinoma

Currently open trials in the same condition.

NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108 · Phase 3 · recruiting
NCT06652672 — Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma · NA · recruiting
NCT06640166 — Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Co · Phase 2 · recruiting
NCT05710406 — Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer · Phase 2, PHASE3 · active not recruiting

Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

Trials by the same sponsor.

NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06709885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Last refreshed: 29 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06709885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing